CRBU (Caribou Biosciences, Inc.) Stock Financials & Earnings | Market Cap Arena

CRBU (Caribou Biosciences, Inc.) Stock Financials & Earnings | Market Cap Arena

CRBUCaribou Biosciences, Inc.

Mkt Cap$186M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$11M

Net Income (TTM)-$148M

EPS (TTM)-$1.59

Free Cash Flow (TTM)-$112M

Gross Margin88.2%

Op. Margin-1329.4%

Net Margin-1327.4%

FCF Margin-1006.8%

P/S Ratio (TTM)16.7x

P/E Ratio (TTM)—

YoY Rev Growth+11.7%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$4M	-$22M	-$31M
Q2 23	$4M	-$23M	-$33M
Q3 23	$24M	-$5M	-$15M
Q4 23	$4M	$2M	-$37M
Q1 24	$2M	$2M	-$46M
Q2 24	$3M	$3M	-$44M
Q3 24	$2M	$2M	-$38M
Q4 24	$2M	-$28M	-$39M
Q1 25	$2M	$2M	-$43M
Q2 25	$3M	$3M	-$48M
Q3 25	$2M	$2M	-$29M
Q4 25	$4M	$3M	-$28M

Valuation

Quarter	P/S	P/E
Q1 23	12.7x	—
Q2 23	13.1x	—
Q3 23	5.4x	—
Q4 23	5.4x	—
Q1 24	5.6x	—
Q2 24	5.6x	—
Q3 24	16.2x	—
Q4 24	18.6x	—
Q1 25	18.8x	—
Q2 25	20.4x	—
Q3 25	20.0x	—
Q4 25	16.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$28M	-$30M
Q2 23	-$15M	-$18M
Q3 23	-$29M	-$34M
Q4 23	-$21M	-$24M
Q1 24	-$37M	-$40M
Q2 24	-$33M	-$35M
Q3 24	-$33M	-$33M
Q4 24	-$35M	-$36M
Q1 25	-$37M	-$38M
Q2 25	-$28M	-$29M
Q3 25	-$25M	-$25M
Q4 25	-$21M	-$21M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$2M
Q2 23	$3M
Q3 23	$5M
Q4 23	$2M
Q1 24	$3M
Q2 24	$2M
Q3 24	$673K
Q4 24	$518K
Q1 25	$1M
Q2 25	$418K
Q3 25	$115K
Q4 25	$216K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+31.5%	+47.2%
Q2 23	-10.4%	+12.3%
Q3 23	+616.4%	+28.3%
Q4 23	-3.6%	+19.6%
Q1 24	-30.6%	+39.9%
Q2 24	-7.7%	+28.2%
Q3 24	-91.4%	+5.1%
Q4 24	-41.6%	-0.1%
Q1 25	-3.1%	-6.5%
Q2 25	-23.0%	+7.0%
Q3 25	+8.6%	-21.5%
Q4 25	+89.7%	-20.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$3M	89.4%
Q2 23	$4M	95.5%
Q3 23	$3M	14.7%
Q4 23	$4M	99.9%
Q1 24	$4M	164.2%
Q2 24	$5M	136.8%
Q3 24	$4M	201.0%
Q4 24	$4M	188.3%
Q1 25	$4M	165.0%
Q2 25	$3M	117.3%
Q3 25	$3M	133.3%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$26M	$9M	—
Q2 23	$27M	$10M	—
Q3 23	$29M	$10M	—
Q4 23	$31M	$10M	—
Q1 24	$34M	$15M	—
Q2 24	$35M	$11M	—
Q3 24	$30M	$10M	—
Q4 24	$30M	$10M	—
Q1 25	$36M	$10M	—
Q2 25	$28M	$10M	—
Q3 25	$22M	—	$9M
Q4 25	$24M	—	$8M

Revenue Segments

Quarter	Reportable Segment
Q1 25	$2M
Q2 25	$3M
Q3 25	$2M
Q4 25	$4M

Revenue by Geography

Quarter	Non-US	United States
Q1 23	$117K	$3M
Q2 23	$9K	$4M
Q3 23	$377K	$23M
Q4 23	$1M	$2M
Q1 24	$160K	$2M
Q2 24	$20K	$3M
Q3 24	$367K	$2M
Q1 25	$129K	$2M
Q2 25	$1M	$2M
Q3 25	$377K	$2M
Q4 25	$170K	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$53M	$176M	$229M
Q2 23	$66M	$193M	$259M
Q3 23	$104M	$234M	$338M
Q4 23	$51M	$278M	$329M
Q1 24	$49M	$245M	$294M
Q2 24	$38M	$224M	$262M
Q3 24	$32M	$196M	$228M
Q4 24	$16M	$193M	$210M
Q1 25	$29M	$179M	$208M
Q2 25	$25M	$159M	$184M
Q3 25	$11M	$136M	$147M
Q4 25	$12M	$127M	$139M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	61M	+0.3%
Q2 23	61M	+0.4%
Q3 23	84M	+36.4%
Q4 23	88M	+5.5%
Q1 24	89M	+1.0%
Q2 24	90M	+1.2%
Q3 24	90M	+0.1%
Q4 24	90M	-0.2%
Q1 25	93M	+2.6%
Q2 25	93M	+0.4%
Q3 25	93M	+0.3%
Q4 25	95M	+1.3%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 19	—	—
FY 20	—	—
FY 21	$97K	99
FY 22	$101K	137
FY 23	$218K	158
FY 24	$68K	147
FY 25	$328	34K